4.3348

5.71% 0.2348

Adc Therapeutics Sa (ADCT)

Overview News Price History Option Chain Discussions Forecast

Adc Therapeutics Sa stock is traded at $4.3348, with a volume of 522.97K. It is up +5.71% in the last 24 hours and up +20.06% over the past month. ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Previous Close:

$4.10

Open:

$4.11

24h Volume:

522.97K

Relative Volume:

0.50

Market Cap:

$537.63M

Revenue:

$69.56M

Net Income/Loss:

$-240.05M

P/E Ratio:

-1.4694

EPS:

-2.95

Net Cash Flow:

$-121.90M

1W Performance:

+8.62%

1M Performance:

+20.06%

6M Performance:

+36.29%

1Y Performance:

+165.89%

1-Day Range:

$4.11

$4.40

1-Week Range:

$3.845

$4.40

52-Week Range:

$1.05

$4.80

Adc Therapeutics Sa Stock (ADCT) Company Profile

Name

Adc Therapeutics Sa

Sector

Healthcare (1117)

Industry

Biotechnology (619)

Phone

41 21 653 02 00

Address

BIOPOLE, EPALINGES

Employee

263

Twitter

Next Earnings Date

2025-03-21

Latest SEC Filings

ADCT's Discussions on Twitter

Compare ADCT vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ADCT Adc Therapeutics Sa	4.34	507.90M	69.56M	-240.05M	-121.90M	-2.95
VRTX Vertex Pharmaceuticals Inc	485.71	121.15B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	785.50	82.43B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	828.96	52.25B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	330.68	44.59B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	366.48	40.07B	4.98B	69.60M	525.67M	0.5198

Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-08-24	Initiated	Stephens	Overweight
May-30-24	Initiated	Cantor Fitzgerald	Overweight
Mar-28-24	Initiated	Guggenheim	Buy
Aug-10-23	Upgrade	JP Morgan	Underweight → Neutral
Apr-24-23	Downgrade	BofA Securities	Neutral → Underperform
Dec-06-22	Initiated	CapitalOne	Overweight
Nov-09-22	Downgrade	BofA Securities	Buy → Neutral
Sep-21-22	Initiated	JP Morgan	Overweight
Sep-09-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-09-21	Initiated	Wolfe Research	Outperform
Aug-17-21	Resumed	Jefferies	Buy
Aug-09-21	Initiated	RBC Capital Mkts	Outperform
Jun-15-21	Initiated	Cantor Fitzgerald	Overweight
Dec-03-20	Initiated	Stifel	Hold
Oct-29-20	Initiated	H.C. Wainwright	Buy
Jun-09-20	Initiated	BofA/Merrill	Buy
Jun-09-20	Initiated	Cowen	Outperform

View All

Adc Therapeutics Sa Stock (ADCT) Latest News

08:12 AM

ADC Therapeutics Amends HealthCare Royalty Financing Agreement - marketscreener.com

08:12 AM

07:51 AM

ADC Therapeutics Amends Royalty Deal, Issues New Warrants - TipRanks

07:51 AM

07:49 AM

ADC Therapeutics amends royalty deal with HealthCare Royalty By Investing.com - Investing.com Canada

07:49 AM

07:40 AM

Stepan Co recently released a project impact forecast, estimating that the cash impact over the entire project cycle will range between $29 million and $44 million, while the non-cash impact is expected to be between $58 million and $62 million. - Bitget

07:40 AM

07:37 AM